This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded ACGL, ASTS, PS, LNTH and ADBE, cutting ratings and price targets; ASTS target fell to $54 and Adobe’s to $267.
Stocks · News reference
Insmed Reaffirms FY26 Revenue Guidance Of $1.25B-$1.40B For BRINSUPRI And $450M- $470M For ARIKAYCE
Reaffirms Full-Year 2026 GuidanceAs Insmed continues to build on its operational excellence and momentum, the Company reaffirms its full-year 2026 financial guidance of revenue in the range of $1.25 billion to $1.40
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.
Wolfe Research Downgrades Insmed to Peer Perform
Wolfe Research analyst Andy Chen downgrades Insmed (NASDAQ:INSM) from Outperform to Peer Perform.
HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target
HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.